Oregon's Cascade Chemistry looks to boost its American-made API production with $14M investment
Amid heightened calls for American-made drugs, a suite of contract manufacturers are making big investments to boost supply. Now, an Oregon CDMO is stepping up to the plate to grow its API contract business.
Cascade Chemisty will triple its total floor space with a $14 million investment, the company said in a press release. Site construction is already underway on a 28,000 square-foot building, which will include suites for Phase I and Phase II manufacturing with flow hydrogenation and reactors up to 400 liters.
Additional capacity for Phase III production of API as well as commercial scale manufacturing bandwidth up to 1,000 liters will be added in 2022. A second building totaling 7,000 square feet is reserved for future expansion, the company said.
The new facilities are expected to be fully operational in the first quarter of 2022 and will also include 2,200 square feet of new analytical labs, a robust quality system and additional office space.
“Demand has outstripped our cGMP manufacturing capacity,” Cascade president Jeremiah Marsden said in a statement. “We were fortunate to acquire two suitable buildings just 10 minutes from our current facility, and construction of new cGMP manufacturing suites that will greatly increase our clinical trial API production capacity is now underway.”
Cascade has had a presence in Oregon for over four decades, formed originally as a chemistry outsourcing company called Organic Consultants. In 2012, Marsden bought the company and rebranded it as Cascade — named after the nearby Oregon mountain range.
Since then, the company has grown through a focus on process chemistry and scaling up its API manufacturing capabilities. Most recently, Cascade partnered in June with Renibus Therapeutics to produce the APIs for RBT-9, an investigational therapeutic entering a Phase II trial for treating Covid-19 patients at high risk of deteriorating health due to age or comorbidities.
“Cascade’s ability to move quickly to design, implement, and scale-up a comprehensive RBT-9 API manufacturing strategy has been one of the essential elements in our campaign to initiate clinical trials with minimal delay,” Alvaro Guillem, Renibus’ CEO said at the time.